Novartis CEO makes mark with $8.7bn AveXis acquisition
April 9, 2018Sales and Marketing AveXis, Novartis, biotech, drugs, gene therapy, pharma, pharmaceutical
Vas Narasimhan’s first few moves as CEO of Novartis indicate that he is not afraid to take bold risks in …
Samsung Bioepis and Biogen secure licensing deal with Abbvie for Humira biosimilar
April 6, 2018Medical Communications, Sales and Marketing AbbVie, Biogen, Humira, Imraldi, Samsung Bioepis, biosimilar, pharma
Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie …
Top Ten most popular articles on Pharmafile.com this week
April 6, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Boehringer Ingelheim, Kite, Nordic Nanovector, Pfizer, Roche, Sanofi, biotech, cystic fibrosis, drugs, pharma, pharmaceutical
Some of the biggest news this week concerns companies that are looking to move on parts of their business, but …
Roche suffers Ocrevus knockback by NICE
April 6, 2018Medical Communications, Sales and Marketing Ocrevus, Roche, biotech, drugs, multiple sclerosis, pharma, pharmaceutical
Roche’s multiple sclerosis drug, Ocrevus (ocrelizumab), has been a big new growth driver for the company, especially in the US, …
J&J pays out $37m in damages over claims its talc contains asbestos
April 6, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, mesothelioma, ovarian cancer, pharma, talc
Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out …
Takeda move for Shire looks increasingly likely
April 6, 2018Medical Communications, Sales and Marketing Japan, Shire, Takeda, UK, biotech, drugs, pharma, pharmaceutical
Takeda’s surprise announcement, just last week, that it was weighing up a move for Shire had some analysts sceptical about …
Nordic Nanovector CEO steps down as company delays R&D timelines
April 5, 2018Medical Communications, Research and Development, Sales and Marketing Luigi Costa, Nordic Nanovector, pharma
Norwegian biopharmaceutical firm Nordic Nanovector has revealed that its Chief Executive Officer Luigi Costa is set to step down from …
Transforming cystic fibrosis treatment
April 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical
Fred van Goor, Principle Research Fellow at Vertex Pharmaceuticals, discusses his history of work in cystic fibrosis and how the …
Roche snaps up Inception neuroscience program
April 5, 2018Sales and Marketing Pipeline Therapeutics, Roche, biotech, drugs, pharma, pharmaceutical
Back in 2014, Roche entered into strategic collaboration with Inception Sciences to look into the regenerative medicines space for multiple …
Boehringer teams up with OSE in €1.1 billion cancer drug partnership
April 5, 2018Sales and Marketing Boehringer, Cancer, OSE Immunotherapeutics, partnership, pharma
Boehringer Ingelheim and biotech firm OSE Immunotherapeutics have announced that they have entered an exclusive collaboration and license agreement to …
Obesity admissions double in four years
April 5, 2018Medical Communications NHS, UK, biotech, drugs, pharma, pharmaceutical
New figures show that hospital admissions related to obesity have doubled over the last four years in the UK, placing …
Lilly and Sigilon team up in $473m+ deal to ‘cure’ diabetes
April 5, 2018Sales and Marketing Eli Lilly, Sigilon Therapeutics, biotech, drugs, pharma, pharmaceutical
Eli Lilly and Sigilon Therapeutics have announced a partnership that looks to break new ground in the management of type …
NICE rejects Dupixent for atopic dermatitis on cost grounds, Sanofi responds
April 4, 2018Research and Development, Sales and Marketing Dupixent, NICE, Sanofi, atopic dermatitis, eczema, pharma
UK drug watchdog NCIE has issued draft guidance rejecting the routine use of Sanofi’s Dupixent (dupilumab) for the treatment of …
Proton beam therapy finally arrives in UK
April 4, 2018Medical Communications, Research and Development NHS, Proton beam therapy, biotech, drugs, pharma, pharmaceutical
28 years after the US first pioneered proton beam therapy at Loma Linda University Medical Center, the UK now has …
Twin-drug combo effectively shrinks lung cancers by blocking their “escape route”
April 4, 2018Research and Development Cancer, epidermal growth factor, lung cancer, pharma, tumour necrosis factor
A study conducted by researchers at UT Southwestern’s Simmons Cancer Center has revealed that a combination of two specific drug …
Pfizer running out of options for consumer business
April 4, 2018Research and Development, Sales and Marketing P&G, Pfizer, Procter & Gamble, biotech, drugs, pharma, pharmaceutical
A surprise new name was thrown into the ring to take on Pfizer’s healthcare unit but speculation suggests that valuation …
Ex-Kite execs form a CAR T rival
April 4, 2018Research and Development, Sales and Marketing Allogene, Pfizer, biotech, drugs, pharma, pharmaceutical
After working to bring through Kite Pharma from the pre-clinical development stage to its final $12 billion acquisition by Gilead, …
Patient experience: Living with ovarian cancer
April 3, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Ingrid Copperman, feature, ovarian cancer, patient experience, pharma
Ingrid Copperman recounts the many ways she has dealt with her diagnosis, as well as how the power of social …
One centre for cancer diagnoses trialled
April 3, 2018Manufacturing and Production, Medical Communications, Sales and Marketing NHS, biotech, drugs, pharma, pharmaceutical
NHS England is trialling centres that should be able to provide rapid answers as to whether a patient has cancer …
Alkermes sent reeling as FDA refuses review of depression treatment
April 3, 2018Manufacturing and Production, Research and Development, Sales and Marketing Alkermes, FDA, depression, major depressive disorder, pharma
Alkermes shares were knocked down to their lowest level since October 2016 after it was revealed that the FDA had …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
